[Risk factors and regularity of transaminase elevation associated with primary Epstein-Barr virus infection in

Y H Zhang1, F Li1, P Shi2

  • 1Department of Infectious Diseases, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai 201102, China.

Insights

Pediatric primary Epstein-Barr virus (EBV) infection can cause elevated transaminases, with age being a significant risk factor. Most children recover within eight weeks, but monitoring is essential for managing liver enzyme levels.

Area of Science:

  • Pediatrics
  • Infectious Diseases
  • Hepatology

Background:

  • Pediatric primary Epstein-Barr virus (EBV) infection is common.
  • Elevated transaminases (ALT, AST) can accompany EBV infection.
  • Understanding risk factors and recovery patterns is crucial for clinical management.

Purpose of the Study:

  • To identify risk factors for elevated transaminases in children with primary EBV infection.
  • To analyze the recovery patterns of alanine transaminase (ALT) and aspartate transaminase (AST) levels.
  • To determine the correlation between elevated transaminases and factors like age, gender, fever duration, and EBV-DNA load.

Main Methods:

  • Retrospective analysis of clinical data from 399 children with primary EBV infection.
  • Logistic regression used to assess correlations between elevated ALT/AST and clinical factors.
  • Calculation of cumulative recovery rates for transaminase levels over time.

Main Results:

  • Over half (51.9%) of the children experienced elevated transaminases.
  • Age was identified as a significant risk factor for transaminase elevation (OR=1.13, P<0.05).
  • Transaminases normalized within approximately 3 weeks for half of the patients and within 8 weeks for most.

Conclusions:

  • Age is a key risk factor for transaminase elevation in pediatric primary EBV infection.
  • Most children achieve normal transaminase levels within two months.
  • The study provides insights into the clinical course and recovery of liver enzymes in EBV-infected children.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
47
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
37
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
45
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
41
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
427
Barrett Esophagus-I: Introduction01:21

Barrett Esophagus-I: Introduction

Barrett's esophagus is a medical condition where the esophageal mucosa is significantly damaged by stomach acid or other digestive fluids, often due to long-term exposure associated with gastroesophageal reflux disease (GERD). In GERD, a weakened or abnormally relaxed lower esophageal sphincter allows stomach acid to flow persistently into the esophagus.
This constant acid exposure transforms the esophagus's pink mucosal lining (stratified squamous epithelium) into a type of lining more...
284